Genomics Data Analytics and Machine Learning in FDA Clinical Research
Dr. Wei-Lun Alterovitz is a senior bioinformatics data scientist doing biomedical research in the Center for Biologics Evaluation and Research (CBER) at FDA. She is currently focusing on establishing informatics methodologies to classify phenotypes, adverse outcomes, and disease-causing genotypes to better understand pathogenesis, molecular mechanisms of diseases and their effects to patient-related outcomes. Dr. Alterovitz is also interested in real-world data, evidence, and use cases of deep learning algorithms in drug discovery process to improve clinical trial design and possible treatment outcomes. Her ultimate goal is applying AI and data analytics to the healthcare industry to improve public health.